Boston Scientific Corporation revenue by year
Over the 10 fiscal years shown, revenue went from $9.08B (year ended Dec 31, 2016) to $20.07B (year ended Dec 31, 2025), a compound annual growth rate of 9.2%. The fastest growth was +19.9% in the year ended Dec 31, 2021; the weakest year was −7.7% (year ended Dec 31, 2020).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $20.07B | +19.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 17, 2026 |
| Dec 31, 2024 | $16.75B | +17.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 17, 2026 |
| Dec 31, 2023 | $14.24B | +12.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 17, 2026 |
| Dec 31, 2022 | $12.68B | +6.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 18, 2025 |
| Dec 31, 2021 | $11.89B | +19.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 20, 2024 |
| Dec 31, 2020 | $9.91B | −7.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 23, 2023 |
| Dec 31, 2019 | $10.73B | +9.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 23, 2022 |
| Dec 31, 2018 | $9.82B | +8.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 23, 2021 |
| Dec 31, 2017 | $9.05B | −0.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2020 |
| Dec 31, 2016 | $9.08B | +12.5% | Revenues | 10-K filed Feb 23, 2017 |
Boston Scientific Corporation reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 30, 2026 | $5.14B | +1.4% | 10-Q filed Nov 2, 2026 |
| 3 months ended Jun 30, 2026 | $5.44B | +7.5% | 10-Q filed Aug 3, 2026 |
| 3 months ended Mar 31, 2026 | $5.20B | +11.6% | 10-Q filed May 1, 2026 |
| 3 months ended Sep 30, 2025 | $5.07B | +20.3% | 10-Q filed Nov 2, 2026 |
| 3 months ended Jun 30, 2025 | $5.06B | +22.8% | 10-Q filed Aug 3, 2026 |
| 3 months ended Mar 31, 2025 | $4.66B | +20.9% | 10-Q filed May 1, 2026 |
| 3 months ended Sep 30, 2024 | $4.21B | +19.3% | 10-Q filed Nov 3, 2025 |
| 3 months ended Jun 30, 2024 | $4.12B | +14.5% | 10-Q filed Aug 1, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 885725 (raw data). Most recent filing in this dataset: 10-Q filed Nov 2, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.